ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Chinese multidisciplinary expert consensus on the management of adverse drug reactions associated with savolitinib

Zhang, Li; Wang, Yongsheng; Lin, Lizhu; Yu, Yongfeng; Lu, Shun*广州中医药大学; 上海交通大学; 四川大学; 中国医学科学院; 中国医学科学院北京协和医院; 1
Therapeutic Advances in Medical Oncology2023DOI: 10.1177/17588359231216089
6阅读
引用收藏
分享

摘要

Savolitinib is a highly selective mesenchymal-epithelial transition (MET) tyrosine kinase inhibitor (TKI). Based on its significant efficacy shown in clinical studies, savolitinib was conditionally approved for marketing in China on 22 June 2021, for the treatment of advanced non-small cell lung cancer (NSCLC) with MET 14 exon skipping mutation. Additionally, many studies showed that MET TKIs were equally effective in patients with advanced solid tumors with MET gene amplification or MET protein overexpression. Several relevant registered clinical studies are in progress. The most common adverse reactions (ARs) due to savolitinib administration are nausea, vomiting, peripheral edema, pyrexia, and hepatotoxicity. This consensus was developed through two rounds of extensive national surveys involving multidisciplinary experts in China, aiming to guide clinicians to prevent and treat various ARs scientifically, and improve the efficacy of the drug and the quality of life of patients.

学科与关键词

关键词
adverse reactionsconsensusmalignant tumorMETsavolitinib
相关
加载中…
  • A Phase 3b Study of 1L Savolitinib in Patients with Locally Advanced or Metastatic NSCLC Harboring MET Exon 14 Mutation
    Lu, S.; Yu, Y.; Guo, Q.; Li, Y.; Zhong, D.; Gu, L.; Fang, J.; Han, S.; Pan, P.; Deng, P.; Liu, B.; Wang, M.; Wu, H.; Gao, F.; Lin, W.; Li, J.; Lv, D.; He, S.; Liu, Z.; Pan, C.; Li, J.; Tian, Y.; Yang, N.; Zhang, Y.; Liu, C.; Zhu, X.; Song, Q.; Yu, J.; Fan, S.; Ren, Y.; Shi, M.; Su, W.被引 1
  • Final OS results and subgroup analysis of savolitinib in patients with MET exon 14 skipping mutations (METex14+) NSCLC
    Lu, S.; Fang, J.; Li, X.; Cao, L.; Zhou, J.; Guo, Q.; Liang, Z.; Cheng, Y.; Jiang, L.; Yang, N.; Han, Z.; Shi, J.; Chen, Y.; Xu, H.; Zhang, H.; Chen, G.; Ma, R.; Sun, S.; Fan, Y.; Weiguo, S.European Lung Cancer Congress (ELCC), ELECTR NETWORK, 2022-03-30 To 2022.被引 6
  • SANOVO: A Phase 3 Study of Savolitinib or Placebo in Combination with Osimertinib in Patients with EGFR-mutant and MET Overexpressed NSCLC
    Zhou, Q.; Li, J.; Wang, J.; Yang, L.; Fang, J.; Dong, X.; Yi, T.; Min, X.; Xu, F.; Chen, J.; Zhong, D.; Bai, J.; Liu, L.; Zeng, A.; Tang, J.; Wu, H.; Luo, X.; Yu, J.; Su, W.; Wu, Y. -L.
查看全部 →

发表信息

论文状态
公开发表
期刊
Therapeutic Advances in Medical Oncology
发表日期
2023
卷期
第 15 卷
页码
17588359231216089
DOI
10.1177/17588359231216089
语言
ENGLISH
成果收录
SCIE

作者

  • Z

    Zhang, Li (第一作者)

    chinese acad med sci · peking union med coll hosp

  • W

    Wang, Yongsheng

    sichuan univ

查看全部 5 位作者收起作者
  • L

    Lin, Lizhu

    1 · guangzhou univ chinese med

  • Y

    Yu, Yongfeng

    shanghai jiao tong univ

  • L

    Lu, Shun (通讯)

    shanghai jiao tong univ

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417